ofatumumab · Medicine question

What interaction risk is associated with combining ofatumumab (Kesimpta) with other immunosuppressive therapies?

Name: What interaction risk is associated with combining ofatumumab (Kesimpta) with other immunosuppressive therapies?
Published: 2026-11-08T01:58:04.374Z

iatroX medicinesPublished 8 November 2026

The answer

Answer

Combining ofatumumab (Kesimpta) with other immunosuppressive therapies carries a risk of additive immune system effects, including additive immunosuppression.

Sources for this answer

Kesimpta 20 mg solution for injection in pre-filled penNovartis Pharmaceuticals UK Ltd · emc · SmPC §4.5 Interaction with other medicinal products · Version 7Document updated 16 June 2026

Sources checked 8 November 2026

loading page…

Answer

Sources for this answer

Answer

Sources for this answer

More questions about ofatumumab